DE69933468T3 - Adenovirus-vermittelte gentherapie - Google Patents

Adenovirus-vermittelte gentherapie Download PDF

Info

Publication number
DE69933468T3
DE69933468T3 DE69933468T DE69933468T DE69933468T3 DE 69933468 T3 DE69933468 T3 DE 69933468T3 DE 69933468 T DE69933468 T DE 69933468T DE 69933468 T DE69933468 T DE 69933468T DE 69933468 T3 DE69933468 T3 DE 69933468T3
Authority
DE
Germany
Prior art keywords
tumor
adenovirus
patients
gene
gene therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69933468T
Other languages
German (de)
English (en)
Other versions
DE69933468D1 (de
DE69933468T2 (de
Inventor
Seppo YLA-HERTTUALA
Anu-Maaria Sandmair
Sami LOIMAS
Matti Vapalahti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ark Therapeutics Ltd
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69933468(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Publication of DE69933468D1 publication Critical patent/DE69933468D1/de
Publication of DE69933468T2 publication Critical patent/DE69933468T2/de
Application granted granted Critical
Publication of DE69933468T3 publication Critical patent/DE69933468T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69933468T 1998-11-06 1999-11-05 Adenovirus-vermittelte gentherapie Expired - Lifetime DE69933468T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9824437.9A GB9824437D0 (en) 1998-11-06 1998-11-06 Gene therapy
GB9824437 1998-11-06
PCT/EP1999/009017 WO2000028059A1 (en) 1998-11-06 1999-11-05 Adenovirus-mediated gene therapy
EP99971860A EP1135513B2 (en) 1998-11-06 1999-11-05 Adenovirus-mediated gene therapy

Publications (3)

Publication Number Publication Date
DE69933468D1 DE69933468D1 (de) 2006-11-16
DE69933468T2 DE69933468T2 (de) 2007-01-11
DE69933468T3 true DE69933468T3 (de) 2012-01-19

Family

ID=10842035

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69933468T Expired - Lifetime DE69933468T3 (de) 1998-11-06 1999-11-05 Adenovirus-vermittelte gentherapie

Country Status (18)

Country Link
US (1) US6579855B1 (cg-RX-API-DMAC7.html)
EP (1) EP1135513B2 (cg-RX-API-DMAC7.html)
JP (1) JP4733833B2 (cg-RX-API-DMAC7.html)
KR (1) KR20020013473A (cg-RX-API-DMAC7.html)
CN (1) CN1184321C (cg-RX-API-DMAC7.html)
AT (1) ATE341639T1 (cg-RX-API-DMAC7.html)
AU (1) AU749451B2 (cg-RX-API-DMAC7.html)
CA (1) CA2348624C (cg-RX-API-DMAC7.html)
CY (1) CY1106198T1 (cg-RX-API-DMAC7.html)
DE (1) DE69933468T3 (cg-RX-API-DMAC7.html)
DK (1) DK1135513T4 (cg-RX-API-DMAC7.html)
ES (1) ES2273521T5 (cg-RX-API-DMAC7.html)
GB (1) GB9824437D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0104046A3 (cg-RX-API-DMAC7.html)
NO (1) NO330776B1 (cg-RX-API-DMAC7.html)
PL (1) PL193076B1 (cg-RX-API-DMAC7.html)
PT (1) PT1135513E (cg-RX-API-DMAC7.html)
WO (1) WO2000028059A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910950D0 (en) 2009-06-24 2009-08-05 Ark Therapeutics Ltd Filtration
GB0916997D0 (en) * 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
US20130296407A1 (en) * 2011-01-18 2013-11-07 Ark Therapeutics, Ltd. Combination Therapy for Cancer
GB201100804D0 (en) * 2011-01-18 2011-03-02 Ark Therapeutics Ltd Drug combination
SG10201604810UA (en) 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US20160058888A1 (en) * 2013-05-08 2016-03-03 Gliotherapy Limited Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir
CN105813579B (zh) 2013-08-08 2019-05-07 全球生物疗法有限公司 用于微创手术过程的夹具装置和其应用
DE102019000490A1 (de) 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
KR20230009430A (ko) 2020-05-12 2023-01-17 리제너론 파아마슈티컬스, 인크. 신규 il10 효능제 및 그의 사용 방법
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
US12559576B2 (en) 2021-11-11 2026-02-24 Regeneron Pharmaceuticals, Inc. CD20-PD1 binding molecules and methods of use thereof
AU2024207005A1 (en) 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
WO2024233926A1 (en) 2023-05-10 2024-11-14 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
KR20260113057A (ko) 2023-11-14 2026-07-21 리제너론 파아마슈티컬스, 인크. 조작된 중쇄 가변 도메인 및 이의 용도
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
US6579855B1 (en) 2003-06-17
AU749451B2 (en) 2002-06-27
PT1135513E (pt) 2006-12-29
DE69933468D1 (de) 2006-11-16
HUP0104046A3 (en) 2003-09-29
ES2273521T5 (es) 2011-12-28
CY1106198T1 (el) 2011-06-08
CN1325450A (zh) 2001-12-05
DE69933468T2 (de) 2007-01-11
CA2348624A1 (en) 2000-05-18
NO20012220L (no) 2001-05-04
NO20012220D0 (no) 2001-05-04
AU1385100A (en) 2000-05-29
EP1135513B1 (en) 2006-10-04
ATE341639T1 (de) 2006-10-15
JP4733833B2 (ja) 2011-07-27
PL349489A1 (en) 2002-07-29
PL193076B1 (pl) 2007-01-31
NO330776B1 (no) 2011-07-11
HUP0104046A2 (hu) 2002-01-28
EP1135513B2 (en) 2011-08-10
KR20020013473A (ko) 2002-02-20
CN1184321C (zh) 2005-01-12
DK1135513T4 (da) 2011-11-21
DK1135513T3 (da) 2006-11-27
WO2000028059A1 (en) 2000-05-18
GB9824437D0 (en) 1999-01-06
ES2273521T3 (es) 2007-05-01
CA2348624C (en) 2012-07-31
JP2002529097A (ja) 2002-09-10
EP1135513A1 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
DE69933468T2 (de) Adenovirus-vermittelte gentherapie
DE69434069T2 (de) Gentherapie für solide tumoren, papillome und warzen
DE69121452T2 (de) Gen-Sequenzentransfer und -exprimierung bei Zellen des zentralen Nervensystems mit mutierenden Herpes-Simplex-Viren, die Deletionen in Viren-Replikationsgenen enthalten
DE69033975T2 (de) Rekombinanttherapien für Infektionen und hyperproliferative Störungen
DE69526853T2 (de) Hemmung der fortpflanzung von arterienglattmuskelzellen
DE60010654T2 (de) Replikativer virus gesteuert von dem promotor der reversen telomerase transkriptase zur behandlung von krebs
DE69132047T2 (de) Gentherapie gegen krankheiten die die zellteilung betreffen
DE69230993T2 (de) Rekombinante viren vektoren zur expression in muskelzellen
DE69535703T2 (de) AAV-vermittelte Zufuhr von DNA an Zellen des Nervensystems
DE60129229T2 (de) Adeno-assoziierte virus-vermittelte übertragung von angiogenesefaktoren
DE60305443T2 (de) Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung
DE69725452T2 (de) Hsv stamm mit mangel für funktionelle icp27 und icp34.5 genen
JP2002501742A (ja) 単純ヘルペスウイルス変異体およびその使用方法
DE69836139T2 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE69431046T2 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
JP2001508294A (ja) 真核細胞遺伝子発現カセットおよびその使用
DE60016429T2 (de) Verwendung Zell-spezifischer und/oder Tumor-spezifischer Promotoren
Durham et al. Toxicity of replication-defective adenoviral recombinants in dissociated cultures of nervous tissue
DE69637123T2 (de) Die expression von cyclin g1 in tumoren
DE60128445T2 (de) Mutiertes cyclin g1 protein
AU740641B2 (en) Method for treating amyotrophic lateral sclerosis
Shimizu et al. Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from tumor bed in patients with malignant glioma
EP1362096B1 (de) Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
DE60024442T2 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie
Vrionis et al. Preservation of the bystander cytocidal effect of irradiated herpes simplex virus thymidine kinase (HSV-tk) modified tumor cells

Legal Events

Date Code Title Description
8363 Opposition against the patent
R102 Epo decision maintaining patent in amended form now final

Ref document number: 1135513

Country of ref document: EP

Effective date: 20110810